Kevin Church - 18 Feb 2022 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Executive VP, Research
Signature
Glenna Mileson, Attorney-in-fact for Kevin Church
Issuer symbol
ATHA
Transactions as of
18 Feb 2022
Net transactions value
+$3,751
Form type
4
Filing time
18 Feb 2022, 18:38:05 UTC
Previous filing
20 Jan 2022
Next filing
10 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATHA Common Stock Options Exercise $3,751 +3,152 +7.1% $1.19 47,566 18 Feb 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Options Exercise $0 -3,152 -100% $0.000000* 0 18 Feb 2022 Common Stock 3,152 $1.19 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option fully vested on September 1, 2017.